Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.

CONCLUSION: In this case the patient was rapidly transitioned from oral selexipag to i.v. and then subcutaneous treprostinil therapy over a 30-hour period, with minimal adverse effects. PMID: 32620953 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32620953?dopt=Abstract

Source: American Journal of Health-System Pharmacy : AJHP - July 3, 2020 Category: Drugs & Pharmacology Authors: Radosevich JJ, DeChristopher A, Irandost M, Fann J, Feldman J Tags: Am J Health Syst Pharm Source Type: research